Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cyclofluidic Announces its Automated Chemical Synthesis-To-Screen Process for Drug Discovery

Published: Wednesday, March 16, 2011
Last Updated: Wednesday, March 16, 2011
Bookmark and Share
Researchers synthesize and test a greater range of potential new medicines in a considerably shorter time frame.

Cyclofluidic‘s technology platform will significantly accelerate the drug discovery process, by giving researchers a platform to synthesize and test a greater range of potential new medicines in a considerably shorter time frame. It is envisaged that this new technology will radically transform drug discovery by improving both the efficiency and the overall cost to the industry.

Cyclofluidic has successfully demonstrated this fully integrated approach encompassing chemical synthesis of a pharmaceutically relevant molecule through to the generation of high quality target screening data. Cyclofluidic’s Chief Operating Officer David Parry commented “Achieving this scientific milestone represents a key stage in the evolution of Cyclofluidic.

We have demonstrated a fully integrated and automated approach to the generation of structure activity data which underpins modern drug discovery. The results illustrate the potential of the Cyclofluidic integrated approach to deliver next generation medicinal chemistry. I am delighted that we have been able to achieve such significant continued progress.”

“The interface between chemical synthesis and biological measurement is an exciting one, and tightening the connection between the two is a key challenge. This result shows that Cyclofluidic are making excellent progress in developing their internal capabilities” said David Klug, Professor of Chemical Biophysics and Head of the Imperial College Institute for Chemical Biology and chair of Cyclofluidic’s Scientific Advisory Board.

Currently, it takes between 12-15 years and a cost of up to US$1 billion to develop a new medicine. A key element of early stage pharmaceutical research is the synthesis and screening of new molecules as potential medicines against therapeutic targets. The research and development activities being undertaken within Cyclofluidic are expected to impact significantly on the timelines for the optimization of potential molecules.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!